



Close

Virogates A/S enters co-development agreement with Austria-based GENSPEED Biotech GmbH to develop a novel, combined suPAR and CRP triage test for use at hospitals, general practitioners & ambulances

Press release

Birkerød, 20 February 2019

ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has commenced a partnership to co-develop a product based on a combination of ViroGates' suPARnostic® and GENSPEED Biotech GmbH's analysis platform GENSPEED®.

The aim is to develop a finger prick test to analyse for suPAR and C Reactive Protein (CRP – an acute phase inflammatory protein) in less than 10 minutes using the small Point of Care instrument from GENSPEED. The Point of Care test will allow health care personnel to easily and rapidly risk classify acute and chronic patients on site, e.g. in ambulances. Immediate results support the decision on whether the patient needs hospital admission or can be treated at a scheduled visit in the hospital or with primary or secondary care physicians.

The product is expected to take approximately two years to complete. The final product will be marketed by ViroGates and developed to support ViroGates' long-term strategy of expanding its business to general practitioners, ambulances and other users outside of the Emergency Department setting.

CEO Jakob Knudsen, says in a comment: "We are excited to work with an experienced partner that will enable us to co-develop a new generation of diagnostic and prognostic testing. We believe, the combination of suPARnostic® and GENSPEED technology will provide fast, easy to obtain and reliable results in both selected hospitals and in outpatient settings. The product will enable patients to be tested at an earlier stage than today, and this will improve the risk stratification process significantly."

Dr. Max Sonnleitner, CEO of GENSPEED Biotech says: "This test will address the unmet market need for fast and reliable test results in a near-patient setting. By providing expected ease of use and multiplexing capabilities, our certified Point of Care testing technology perfectly matches the requirements for outpatient triaging."

For further information contact:

ViroGates A/S

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email: jk@virogates.com

GENSPEED Biotech GmbH

CEO Dr. Max Sonnleitner

Email: max.sonnleitner@genspeed-biotech.com

Tel.: +43 (0) 6642681032

Supplied by © Euroland.com
Terms of Service | Cookie Policy



Close

About ViroGates

ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.

About GENSPEED Biotech GmbH and the GENSPEED® Technology

GENSPEED Biotech offers a unique technology platform on which rapid tests can be developed for medical diagnostics and various industrial applications. The technology combines microfluidics, miniaturized opto-electronics and automation as the proprietary basis of a small, simple, reliable and IVD CE certified test system. The system enables the detection of up to 8 different biomarkers as a multiplex assay on-site within only a few minutes and with high sensitivity. For more information on GENSPEED Biotech please visit www.genspeed-biotech.com.

Attachment

- [20190220 ViroGates_Genspeed press release.pdf](#)

Attachments

[20190220 ViroGates_Genspeed press release.pdf](#)